Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Centessa Pharmaceuticals plc

The latest stock market stories for Tuesday are ready to go in the daily wrap-up.


Morning News Wrap-Up 3/31/26: Today’s Biggest Stock Market Stories!

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Centessa Pharmaceuticals (CNTA), UnitedHealth (UNH) and Adagio Me...

Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (CNTA), UnitedHealth (UNH) and Adagio Medical Holdings (ADGM)

Centessa Pharmaceuticals Plc ($CNTA) announced an update on their ongoing clinical study. The Phase 2 long term extension study NCT07096674 follows...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CNTA	$39.47	-0.20%	2.87M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CNTA	$39.47	-0.2%	2.87M
3
4
5
6

CNTA

CNTA

Get Centessa Pharmaceuticals plc Data in Excel

Get Centessa Pharmaceuticals plc Data in Excel